This broad view is especially relevant to chronomedicine and therapeutics, as circadian disruption is increasingly linked to metabolic syndromes, neurodegenerative conditions, and mood disorders; by classifying compounds into groups such as CRY ligands, melatonin receptor agonists, and steroids, the database provides a crucial resource for focusing on targeted interventions. The gene discussed is CRYL1; the disease is mood disorder.